Zhu Kun, Devine Amanda, Dick Ian M, Wilson Scott G, Prince Richard L
School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia.
J Clin Endocrinol Metab. 2008 Mar;93(3):743-9. doi: 10.1210/jc.2007-1466. Epub 2007 Dec 18.
Effects of long-term calcium, with or without vitamin D, on hip bone mineral density (BMD) and bone turnover in sunny climates have not been reported.
The aim was to evaluate the effect of vitamin D added to calcium supplementation on hip dual-energy x-ray absorptiometry BMD and calcium-related analytes.
DESIGN, SETTING, AND PARTICIPANTS: The study was a 5-yr randomized, controlled, double-blind trial of 120 community-dwelling women aged 70-80 yr.
The interventions were 1200 mg/d calcium with placebo vitamin D (Ca group) or with 1000 IU/d vitamin D2 (CaD group), or double placebo (control).
Hip BMD, plasma 25-hydroxyvitamin D, biomarkers of bone turnover, PTH, and intestinal calcium absorption were measured.
Hip BMD was preserved in CaD (-0.17%) and Ca (0.19%) groups but not controls (-1.27%) at yr 1 and maintained in the CaD group only at yr 3 and 5. The beneficial effects were mainly in those with baseline 25-hydroxyvitamin D levels below the median (68 nmol/liter). At yr 1, compared with controls, the Ca and CaD groups had 6.8 and 11.3% lower plasma alkaline phosphatase, respectively (P<or=0.02), and 28.7 and 34.5% lower urinary deoxypyridinoline to creatinine ratio, respectively (P<or=0.05). At 5 yr, this suppression was maintained only in the CaD group. CaD reduced PTH at 3 and 5 yr cf. controls (27.8 and 31.3%, P<or=0.005) in those with baseline PTH levels above the median (3.6 pmol/liter). Therapy did not affect intestinal calcium absorption at high carrier loads.
Addition of vitamin D to calcium has long-term beneficial effects on bone density in elderly women living in a sunny climate, probably mediated by a long-term reduction in bone turnover rate.
在阳光充足的气候条件下,长期补充钙(无论是否添加维生素D)对髋部骨矿物质密度(BMD)和骨转换的影响尚未见报道。
评估补钙时添加维生素D对髋部双能X线吸收法骨密度及钙相关分析物的影响。
设计、地点和参与者:本研究是一项针对120名年龄在70 - 80岁的社区居住女性进行的为期5年的随机、对照、双盲试验。
干预措施为每日补充1200毫克钙加安慰剂维生素D(钙组)或加1000国际单位/天维生素D2(钙D组),或双安慰剂(对照组)。
测量髋部骨密度、血浆25 - 羟基维生素D、骨转换生物标志物、甲状旁腺激素(PTH)及肠道钙吸收。
在第1年时,钙D组(-0.17%)和钙组(0.19%)的髋部骨密度得以维持,而对照组(-1.27%)则未维持;仅在第3年和第5年时,钙D组的骨密度得以维持。有益效果主要体现在基线25 - 羟基维生素D水平低于中位数(68纳摩尔/升)的人群中。在第1年时,与对照组相比,钙组和钙D组的血浆碱性磷酸酶分别降低了6.8%和11.3%(P≤0.02),尿脱氧吡啶啉与肌酐比值分别降低了28.7%和34.5%(P≤0.05)。在5年时,这种抑制作用仅在钙D组中得以维持。在基线甲状旁腺激素水平高于中位数(3.6皮摩尔/升)的人群中,钙D组在第3年和第5年时降低了甲状旁腺激素水平,与对照组相比(分别降低27.8%和31.3%,P≤0.005)。在高载体负荷下,治疗对肠道钙吸收无影响。
在阳光充足的气候条件下生活的老年女性中,补钙时添加维生素D对骨密度具有长期有益影响,可能是通过长期降低骨转换率来介导的。